Latest Cancer News

FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma (12-5-2019)
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib; BeiGene... Continue Reading

Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) compared Chemotherapy in Advanced Non-Small Cell Lung Cancer (11-29-2019)
The Opdivo plus low-dose Yervoy immunotherapy combination improved long-term survival for patients with advanced non-small cell lung cancer (NSCLCC) across PD-L1 expression levels. (3) Both Opdivo and... Continue Reading

Alunbrig Continues to Demonstrate Superiority in the First – Line After Two Years of Follow-Up for ALK + NSCLC (11-27-2019)
Updated data released 11/2019 from the Phase 3 ALTA-1L clinical trial evaluating Alunbrig (brigatinib) versus Xalkori (crizotinib) in patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small... Continue Reading

More Cancer News

Patient Resources

VirtualTour_280x99

CoC Logo 541 ACCREDITED PROGRAM caps